Elliott Advisors (UK) Limited Statement on thyssenkrupp AG
Further to recent media speculation, funds advised by Elliott Advisors (UK) Limited (“Elliott”) confirm that they are significant shareholders in thyssenkrupp AG (“thyssenkrupp” or the “Company”). The funds’ position in ordinary shares is such that it does not exceed, as of today, the thresholds mandating disclosure under applicable German laws. Elliott will make any disclosure regarding its holdings in the shares of thyssenkrupp no later than when and as required by German law.
Elliott’s approach to its investment in thyssenkrupp is consistent with its approach to all its investments. Elliott has spent significant time and resources analysing the Company, performing exhaustive research on its prospects, competitive positioning and valuation. Elliott believes thyssenkrupp has significant scope for operational improvement which would benefit all stakeholders and looks forward to engaging in a constructive dialogue with them in the near future, including with the supervisory and management boards.
Elliott Management Corporation manages two multi-strategy investment funds which combined have approximately $35 billion of assets under management. Its flagship fund, Elliott Associates, L.P., was founded in 1977, making it one of the oldest funds of its kind under continuous management. The Elliott funds’ investors include pension plans, sovereign wealth funds, endowments, foundations, funds-of-funds, high net worth individuals and families, and employees of the firm. Elliott Advisors (UK) Limited is an affiliate of Elliott Management Corporation.
Sarah Rajani CFA
Elliott Advisors (UK) Limited
+44 (0) 20 3009 1475
Thomas Katzensteiner / Tobias Eberle
Charles Barker Corporate Communications
+49 69 79 40 90 25 / 24
About Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NJ-CELGENE19.7.2019 20:01:04 CEST | Press release
FDA Approves OTEZLA® (apremilast) for the Treatment of Oral Ulcers Associated with Behçet’s Disease
JANSSEN19.7.2019 15:07:11 CEST | Press release
Abiraterone Acetate Included in World Health Organisation’s Essential Medicines List for the Treatment of Metastatic Castration-Resistant Prostate Cancer
CA-GILEAD-SCIENCES19.7.2019 14:32:09 CEST | Press release
Gilead Sciences Licenses Respiratory and Herpes Antiviral Research Programs From Novartis
SCHLUMBERGER-LIMITED19.7.2019 13:02:04 CEST | Press release
Schlumberger Announces Second-Quarter 2019 Results
TX-SCHLUMBERGER-LIMITED19.7.2019 12:48:04 CEST | Press release
Schlumberger Appoints Olivier Le Peuch as CEO
WA-FLUKE-CORPORATION19.7.2019 12:02:10 CEST | Press release
Fluke Corporation Acquires Industrial Reliability Leader PRÜFTECHNIK
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom